ProMIS Neurosciences posts Q3 loss of $11.8 million on increased clinical trial spending
I'm PortAI, I can summarize articles.
ProMIS Neurosciences Inc. reported a Q3 loss of $11.8 million, driven by increased clinical trial spending, with R&D expenses rising to $9.8 million from $2.6 million year-over-year. The accumulated deficit reached $119.7 million, and total shareholders’ equity fell to $9.2 million. The company is advancing its PRECISE-AD trial for PMN310 and has added Slanix Paul Alex to its board. Additional capital was raised to support strategic goals.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments